# US 2016/0256629 A1 · Sensor model supervisor for a closed-loop insulin infusion system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256629 A1
- Document ID: US20160256629A1
- Status: Published application
- Kind: A1
- Application number: 15/138,540
- Filed: 2016-04-26
- Published: 2016-09-08
- Earliest claimed: 2012-08-30
- Assignees: Medtronic MiniMed, Inc.
- Applicants: Medtronic Minimed, Inc.
- Inventors: Benyamin Grosman; Di Wu; Anirban Roy; Neha J. Parikh
- Web page: https://patentgrep.com/patent/US20160256629A1

## CPC

- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61B 5/14503: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence)}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms}
- A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body}
- G16H 20/17: delivered via infusion or injection
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- A61M 2005/14208: {with a programmable infusion control system, characterised by the infusion program}
- A61M 2205/52: with memories providing a history of measured variating parameters of apparatus or patient
- A61M 2230/005: Parameter used as control input for the apparatus
- A61M 2230/201: Glucose concentration
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR

## Abstract

An insulin infusion device includes a processor architecture, and a memory element that stores executable instructions to perform a method of controlling delivery of insulin to a user. The method operates the device in a closed-loop mode to deliver insulin, obtains patient-specific parameters for a current time sample, and estimates a plasma insulin value and a blood glucose value for the user based on at least some of the patient-specific parameters. The estimating is also based on a previously estimated plasma insulin value obtained for a previous time sample, and a previously estimated blood glucose value obtained for the previous time sample. A predicted sensor glucose value is generated for the current time sample, and the closed-loop mode or a safe basal mode is selected for controlling operation of the insulin infusion device in accordance with the selected mode.

## Claims

### Claim 1

An insulin infusion device comprising:
a reservoir for insulin to be delivered from the insulin infusion device to a body of a user;
a processor architecture comprising at least one processor device; and
at least one memory element associated with the processor architecture, the at least one memory element storing processor-executable instructions that, when executed by the processor architecture, perform a method of controlling delivery of insulin from the insulin reservoir to the body of the user, the method comprising:
automatically operating the insulin infusion device in a closed-loop mode to deliver insulin from the insulin reservoir to the body of the user;
obtaining, for a current time sample, a patient-specific insulin gain value (KI), a patient-specific fasting insulin basal rate value (IBasal), a patient-specific fasting blood glucose value (SGBase), a meter blood glucose value (MBG), and an insulin delivered value (Iin) that represents an amount of insulin delivered since a preceding time sample;
estimating, for the current time sample, an estimated plasma insulin value (Ipt) and an estimated blood glucose value (Gt) for the user, the estimating based on at least some of the values of KI, IBasal, SGBase, MBG, and (Iin), and the estimating further based on a previously estimated plasma insulin value obtained for a previous time sample (Ipt-1), and a previously estimated blood glucose value obtained for the previous time sample (Gt-1);
generating, for the current time sample, a predicted sensor glucose value (SGp) for the user, the generating based on the values of Gt and SGBase for the current time sample;
selecting either the closed-loop mode or a safe basal mode, based on at least some of the values of SGp, SG, Ipt, and Gt for the current time sample; and
controlling operation of the insulin infusion device to deliver insulin to the body of the user in accordance with the selected mode.

### Claim 2 (depends on 1)

The insulin infusion device of claim 1, wherein the selecting comprises:
selecting between the closed-loop mode, a first safe basal mode, or a second safe basal mode, the first safe basal mode representing a higher basal rate of insulin relative to the second safe basal mode.

### Claim 3 (depends on 2)

The insulin infusion device of claim 2, wherein the method performed by the processor architecture further comprises:
calculating a difference (SGpThDiff) between the predicted sensor glucose value (SGp) and a low threshold value in accordance with the expression: SGpThDiff=SGp−Low Threshold, wherein the second safe basal mode is selected when SGpThDiff<0.

### Claim 4 (depends on 1)

The insulin infusion device of claim 1, wherein the method performed by the processor architecture further comprises:
collecting, during a predetermined period of time, MBG values, sensor glucose (SG) values from a continuous glucose sensor, meal-related data, insulin history data, and total daily insulin data associated with the user; and
calculating, for each predetermined period of time, the values of KI, IBasal, and SGBase, the calculating based on at least some of the collected MBG values, SG values, meal-related data, insulin history data, and total daily insulin data.

### Claim 5 (depends on 4)

The insulin infusion device of claim 4, wherein the method performed by the processor architecture further comprises:
searching the SG values for a fasting glucose value for the user, wherein the values of IBasal and SGBase are calculated based on an identified fasting glucose value.

### Claim 6 (depends on 1)

The insulin infusion device of claim 1, wherein:
IBasal represents an estimated basal rate needed to maintain the fasting blood glucose value (SGBase) for the user; and
SGBase represents an estimated fasting blood glucose value for the user when insulin is delivered at the fasting insulin basal rate value (IBasal).

### Claim 7 (depends on 1)

The insulin infusion device of claim 1, wherein the method performed by the processor architecture further comprises:
resetting the value of Gt-1 with each new value of MBG in accordance with the expression: Gt-1=MBG−SGBase.

### Claim 8 (depends on 1)

The insulin infusion device of claim 1, wherein the method performed by the processor architecture further comprises:
processing at least some of the values of SGp, SG, Ipt, and Gt for the current time sample to detect a sensor under-reading condition, wherein the safe basal mode is selected only in response to detecting the sensor under-reading condition.

### Claim 9

An insulin infusion system comprising:
a continuous glucose sensor that generates sensor data indicative of sensor glucose values (SG) for a user; and
an insulin infusion device coupled to receive the sensor data generated by the continuous glucose sensor, the insulin infusion device comprising an insulin reservoir for insulin to be delivered from the insulin infusion device to the user, a processor architecture comprising at least one processor device and further comprising at least one memory element associated with the processor architecture, the at least one memory element storing processor-executable instructions that, when executed by the processor architecture, cause the insulin infusion device to perform a method comprising:
automatically operating the insulin infusion device in a closed-loop mode to deliver insulin from the insulin reservoir to the body of the user;
obtaining, for a current time sample, a patient-specific insulin gain value (KI), a patient-specific fasting insulin basal rate value (IBasal), a patient-specific fasting blood glucose value (SGBase), a meter blood glucose value (MBG), and an insulin delivered value (Iin) that represents an amount of insulin delivered since a preceding time sample;
estimating, for the current time sample, an estimated plasma insulin value (Ipt) and an estimated blood glucose value (Gt) for the user, the estimating based on at least some of the values of KI, IBasal, SGBase, MBG, and (Iin), and the estimating further based on a previously estimated plasma insulin value obtained for a previous time sample (Ipt-1), and a previously estimated blood glucose value obtained for the previous time sample (Gt-1);
generating, for the current time sample, a predicted sensor glucose value (SGp) for the user, the generating based on the values of Gt and SGBase for the current time sample;
selecting either the closed-loop mode or a safe basal mode, based on at least some of the values of SGp, SG, Ipt, and Gt for the current time sample; and
controlling operation of the insulin infusion device to deliver insulin to the body of the user in accordance with the selected mode.

### Claim 10 (depends on 9)

The system of claim 9, wherein the selecting comprises:
selecting between the closed-loop mode, a safe nominal basal mode, or a safe low basal mode, the safe nominal basal mode representing a higher basal rate of insulin relative to the safe low basal mode.

### Claim 11 (depends on 9)

The system of claim 9, wherein the method performed by the processor architecture further comprises:
collecting, during a predetermined period of time, MBG values, sensor glucose (SG) values from a continuous glucose sensor, meal-related data, insulin history data, and total daily insulin data associated with the user; and
calculating, for each predetermined period of time, the values of KI, IBasal, and SGBase, the calculating based on at least some of the collected MBG values, SG values, meal-related data, insulin history data, and total daily insulin data.

### Claim 12 (depends on 9)

The system of claim 9, wherein:
IBasal represents an estimated basal rate needed to maintain the fasting blood glucose value (SGBase) for the user; and
SGBase represents an estimated fasting blood glucose value for the user when insulin is delivered at the fasting insulin basal rate value (IBasal).

### Claim 13 (depends on 9)

The system of claim 9, wherein the method performed by the processor architecture further comprises:
resetting the value of Gt-1 with each new value of MBG in accordance with the expression: Gt-1=MBG−SGBase.

### Claim 14 (depends on 9)

The system of claim 9, wherein the method performed by the processor architecture further comprises:
processing at least some of the values of SGp, SG, Ipt, and Gt for the current time sample to detect a sensor under-reading condition, wherein the safe basal mode is selected only in response to detecting the sensor under-reading condition.

### Claim 15

A method of operating an insulin infusion device to regulate delivery of insulin to a body of a user, the method comprising:
obtaining, from a continuous glucose sensor, sensor glucose (SG) values for the user;
calculating, from the obtained SG values, a patient-specific fasting insulin basal rate value (IBasal) and a patient-specific fasting blood glucose value (SGBase), wherein IBasal represents an estimated basal rate needed to maintain SGBase for the user, and wherein SGBase represents an estimated fasting blood glucose value for the user when insulin is delivered at IBasal;
using the values of IBasal and SGBase to calculate, for a current time sample, an estimated plasma insulin value (Ipt) and an estimated blood glucose value (Gt) for the user; and
using the values of Ipt, Gt, SGBase, and SG to select either a closed-loop mode of operation, a safe nominal basal mode of operation, or a safe low basal mode of operation for the insulin infusion device; and
controlling delivery of insulin from the insulin infusion device to the body of the user, in accordance with the selected mode of operation.

### Claim 16 (depends on 15)

The method of claim 15, further comprising:
processing at least some of the values of Ipt, Gt, SGBase, and SG for the current time sample to detect a sensor under-reading condition, wherein the safe low basal mode is selected only in response to detecting the sensor under-reading condition.

### Claim 17 (depends on 15)

The method of claim 15, further comprising:
processing at least some of the values of SGp, SG, It, and Gt for the current time sample to detect a sensor under-reading condition, wherein the safe nominal basal mode is selected only in response to detecting the sensor under-reading condition.
